Manila, Luzvilla L.
HRN: 03-09-14 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/12/2023
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
10/12/2023
10/18/2023
IV
500mg
Q8h
Ameobiasis
Waiting Final Action
Indication: Empiric Type of Infection: Intra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes